Alabama 2025 Regular Session

Alabama House Bill HB79

Introduced
2/4/25  
Refer
2/4/25  
Report Pass
2/11/25  
Refer
2/18/25  

Caption

State Board of Pharmacy and Employers, prohibited from disciplining pharmacists who recommend off-label medical treatments.

Impact

If enacted, HB79 would significantly alter the legal landscape for pharmacists in Alabama. Under this law, pharmacists would not face disciplinary actions from the State Board of Pharmacy or their employers for actions related to off-label use of drugs, provided these actions align with a healthcare professional's directives. This change is intended to empower pharmacists to offer better patient care without fear of losing their licenses or employment, thus promoting collaborative practice between healthcare providers.

Summary

House Bill 79 (HB79) aims to provide protections for pharmacists regarding the recommendation and dispensing of off-label medical treatments. Currently, existing law allows physicians certain protections when prescribing such treatments; however, pharmacists have not been granted similar safeguards. By prohibiting the State Board of Pharmacy and pharmacists' employers from taking adverse actions based on pharmacists' recommendations or fillings of off-label prescriptions, the bill seeks to create a more supportive environment for medical professionals. This move aligns pharmacy practices more closely with physician practices regarding off-label drug use.

Contention

While HB79 is generally viewed favorably by those advocating for broader healthcare practices and patient-centered care, there may still be concern among some stakeholders regarding the implications of allowing off-label prescriptions. Critics might argue that off-label prescribing lacks the rigorous oversight that approved usages receive, and without careful consideration, it could lead to potential misuse or adverse effects. The discussions surrounding the bill may also reflect a tension between the need for regulatory stability and the desire for innovative treatment approaches.

Voting_history

Voting history and public discussion surrounding HB79 have included debates on the appropriate balance between pharmacist autonomy and patient safety. Some opponents may express concerns about the ramifications of increasing off-label uses, potentially leading to controversial treatment methods. However, supporters argue that such protections fortify the healthcare framework in Alabama, enhancing the collaborative relationships among healthcare providers.

Companion Bills

No companion bills found.

Similar Bills

AZ SB1214

Pharmacists; independent testing; treatment

CA AB602

Public postsecondary education: student conduct: controlled substances.

CA AB554

Health care coverage: antiretroviral drugs, drug devices, and drug products.

HI HR146

Requesting The Department Of Commerce And Consumer Affairs To Establish And Convene A Pharmacy Reimbursement Working Group To Explore And Propose Legislation For The 2026 Legislative Session.

HI SCR70

Requesting The Director Of Commerce And Consumer Affairs To Establish And Convene A Pharmacy Reimbursement Working Group To Explore And Propose Legislation For The 2026 Legislative Session.

HI HCR152

Requesting The Department Of Commerce And Consumer Affairs To Establish And Convene A Pharmacy Reimbursement Working Group To Explore And Propose Legislation For The 2026 Legislative Session.

HI SR54

Requesting The Director Of Commerce And Consumer Affairs To Establish And Convene A Pharmacy Reimbursement Working Group To Explore And Propose Legislation For The 2026 Legislative Session.

NJ A4810

Requires NJ FamilyCare reimbursement for comprehensive medication management services provided for certain children by licensed pharmacist.